You are here
Positive Tumor Response Criteria Achieved in Phase 2 Talabostat Non-Small Cell Lung Cancer Trial
"I am very excited about the positive results we have seen in this study. These results allow us to move forward in planning our Phase 3 pivotal program for NSCLC, which we intend to initiate later this year," said Dr. Maggie Uprichard, Senior Vice President and Chief Development Officer at Point. "We are looking forward to presenting the data in detail during our poster session at ASCO on Tuesday, May 17th in Orlando, FL."
Previously Point announced that in addition to the poster on NSCLC, the Company will have 2 abstracts published on its two Phase 2 metastatic melanoma studies at the American Society for Clinical Oncology Annual Meeting, May 13-17 to be held in Orlando, FL.
Talabostat is orally-active and, through a novel mechanism of action, has the potential to inhibit the growth of malignant tumors and to accelerate the reconstitution of the hematopoietic system.
In 2004, the company initiated four Phase 2 clinical trials of talabostat. The trials are studying talabostat in combination with Taxotere(R) for the treatment of advanced NSCLC, talabostat as a single agent to treat advanced metastatic melanoma, talabostat in combination with cisplatin also to treat advanced metastatic melanoma, and talabostat in combination with rituximab to treat advanced chronic lymphocytic leukemia (CLL). Point Therapeutics is also studying talabostat in clinical trials to potentially prevent both neutropenia and anemia. In addition, our portfolio includes two other DPP inhibitors in preclinical development--PT-630 for type 2 diabetes, and PT-510 as a vaccine adjuvant.
Source: Point Therapeutics, Inc.